A Systematic Review on Technical Aspects in the Development of Dry Powder Inhalers (DPI)
|
|
Author:
|
PRIYANKA SATISH GONDHALE, DR. BINOY VARGHESE CHERIYAN
|
Abstract:
|
Bronchial asthma, chronic obstructive pulmonary disease (COPD), and cystic fibrosis (CF) are diseases
characterized by chronic inflammation and increased mucus secretion leading to airflow limitation,
parenchymal destruction and the development of chronic dyspnea. Many patients with COPD are further
affected by acute exacerbations which results in lung malfunction, decreases quality of life and mortality. Dry
powder inhalers are dry free flowing powdered formulations of the drug, prepared by either spray-drying or
micronization of a blend consisting of the drug and suitable inert carrier. DPI formulations are delivered as an
aerosol by using DPI devices. DPI is a choice for drug delivery as they are easy to operate and has greater
patient compliance. Most of the DPIs are bronchodilators, (salmeterol), corticosteroids (Budesonide,
Fluticasone) and Anticholinergics (Tiotropium).Combination of bronchodilators with corticosteroids and
anticholinergic drug can be used for effective management of pulmonary diseases. The drug particles which are
delivered to the lungs are below 5 µm, this is achieved by drug molecules blending with carrier particles
preferably lactose to help provide bulk and facilitate dispersion mechanism. DPI formulations are widely
accepted. A major concern among physicians in their daily clinical practices is that inter and intra patient
variability of the drug dosage delivered to the deep lungs from the inhalation devices. This variability is
dependent on drug formulation, its design and patient inhalation profile. This article is a compilation of various
issues observed in the development of DPI’s.
|
Keyword:
|
Dry powder inhalers, Fine particle dose, uniformity of delivered dose, dose sampling tube apparatus (DUSA), Aerodynamic particle size distribution (APSD), Next generation impactor (NG
|
EOI:
|
-
|
DOI:
|
https://doi.org/10.31838/ijpr/2021.13.01.688
|
Download:
|
Request For Article
|
|
|